Objective Correct preoperative identification of high-risk patients is important to optimise surgical treatment and improve survival. We wanted to explore if asparaginase-like protein 1 (ASRGL1) expression in curettage could predict lymph node metastases and poor outcome, potentially improving preoperative risk stratification.
Introduction
Endometrial carcinoma is one of the most common cancers in women in western countries. Surgery is the primary treatment, and the standard procedure includes hysterectomy and bilateral salpingo-oophorectomy. Women with suspected high-risk disease are often scheduled for more radical surgery, including removal of pelvic and/or para-aortic lymph nodes for surgical staging. 1 Curettage histology is used to categorise women with high-and low-risk disease before surgery. Histological evaluation of preoperative endometrial biopsies and hysterectomy specimens is reported to be discordant in 10-33% of cases, [2] [3] [4] [5] [6] [7] [8] suggesting that this preoperative assessment alone is suboptimal for risk stratification and therapeutic planning. 9 Failure to recognise high-risk cases from preoperative biopsies is reported to be associated with poor survival, most likely due to women undergoing less extensive surgery. 2, 3, 8 Standard clinicopathological factors including International Federation of Gynecology and Obstetrics (FIGO) stage and histological grade are assessed postoperatively and are currently the best clinically applied prognostic biomarkers in endometrial carcinoma. 10 Novel biomarkers that can identify high-risk patients before surgery would improve treatment of endometrial carcinoma and allow a more tailored surgical approach for individual women. 11 Imaging techniques like magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography/ computed tomography ( 18 F-FDG-PET/CT) have been demonstrated to be useful in the preoperative staging of endometrial cancer and for identifying high-risk endometrial cancer patients. [12] [13] [14] [15] [16] Also, several molecular markers including estrogen receptor a (ERa) and progesterone receptor (PR) have been explored in curettage samples. 17, 18 Even though some institutions apply imaging or molecular biomarkers in preoperative diagnosis of endometrial carcinoma, such diagnostic tools are currently not in widespread clinical use.
Asparaginase-like protein 1 (ASRGL1) is an enzyme classified as an N-terminal nucleophile hydrolase, demonstrating b-aspartyl peptidase and L-asparaginase activity in vitro. 19 High expression of ASRGL1 is reported in several tumours, including breast, ovarian and cervical cancers. [20] [21] [22] In endometrial carcinoma, ASRGL1 is reported to be a strong biomarker, and loss of gene and protein expression of ASRGL1 has been found to associate with features of aggressive disease and poor survival. [23] [24] [25] [26] Still, the biological importance of ASRGL1 in normal tissues and during cancer development is largely unknown. The aim of this study was to investigate if ASRGL1 level in curettage could be used as a preoperative biomarker to identify women with aggressive disease and lymph node metastases, to tailor the surgical procedure for the individual patient.
Materials and methods

Patient series
In total, 1144 women with endometrial carcinoma from ten hospitals in Norway, Sweden and Belgium were prospectively included in a population-based series between 2001 and 2015. Preoperative curettage samples were collected and prepared as formalin-fixed and paraffinembedded specimens at the respective centres. Clinicopathological information including age at primary treatment, FIGO stage (according to 2009 criteria 27 ), histopathological type and grade of primary tumour and follow-up data was retrieved from medical records as previously described. 3 Mean follow-up time for survivors was 51 months (range 0-147). Preoperative risk assessment of women was based on curettage histology reports, categorising them as low risk (benign; diagnosed with endometrial carcinoma after hysterectomy, complex atypical hyperplasia or endometrioid grade 1-2) or high risk (nonendometrioid histology or endometrioid grade 3). MRI and 18 F-FDG PET/CT have been implemented in the preoperative diagnostic protocol for women with endometrial carcinoma treated at Haukeland University Hospital since 2009 and 2011, respectively. One hundred and thirty-nine women with curettage samples available for evaluation of ASRGL1 had undergone preoperative MRI, and 89 women had undergone preoperative 18 F-FDG PET/CT. All women were treated as recommended by national guidelines. No women underwent sentinel lymph node removal. Neither patients nor the public were involved in the design of the study.
Preoperative MRI and PET/CT imaging and image analysis
Preoperative MRI was performed using a whole-body 1.5-T MRI system (Siemens Avanto running Syngo v. B17, Erlangen, Germany) with a six-channel body coil according to a standardised protocol. 28 Based on the standard anatomical images, tumour volume was estimated by measuring the largest tumour diameter in three orthogonal planes (x, y, z) using the following equation; tumour volume = x * y * z/2. Diffusion-weighted imaging of the pelvis was performed and used for generation of apparent diffusion coefficient maps. Dynamic contrast-enhanced-MRI was acquired with 12 axial slices and a temporal resolution of 2.5 seconds. Blood flow and the transfer constant from extravascular extracellular space to blood were calculated using the extended Tofts kinetic model with a standardised arterial input function. 13 The 18 F-FDG PET/CT images were acquired with a Biograph 40 True Point scanner (Siemens, Erlangen, Germany) using an established protocol. 29 18 F-FDG was administered by intravenous injection 60-120 minutes before scanning. Static PET images were acquired from the meatus of the ear to the proximal thigh at intervals of 3 minutes per bed position. Attenuation correction was conducted using a whole-body low-dose CT scan (120 kV, 50 reference mAs). Maximum standard uptake value (SUV max ) in the tumour was measured, and a volume of interest including voxels with an SUV > 2.5 was generated for estimation of SUV mean and metabolic tumour volume (MTV). Total lesion glycolysis (TLG) was calculated as TLG = SUV mean 9 MTV. 30 
Immunohistochemistry
Formalin-fixed and paraffin-embedded tissue was used to generate tissue microarrays (TMA) from collected samples as previously described. 31 The tumour area with highest tumour cell content was identified on haematoxylin & eosin-stained slides. Using a custom-made precision instrument (Beecher Instruments, Silver Spring, MD, USA), three tissue cylinders (0.6 mm) were punched out of the donor block and mounted in a recipient paraffin block. Both TMA production and immunohistochemistry (IHC) staining were performed at a central site. Automated IHC staining of TMAs was performed using a LabVision Autostainer 480S (Thermo Fisher Scientific, Runcorn, UK). Anti-ASRGL1 monoclonal antibody (AMAb90907; Atlas Antibodies, Stockholm, Sweden) was diluted 1:1000 in UltraAb Diluent (Thermo Fisher Scientific, Freemont, CA, USA) and applied for 30 minutes at room temperature, before a secondary anti-mouse horseradish peroxidase-conjugated reagent (UltraVision, Thermo Fisher Scientific, Runcorn, UK) was applied for 30 minutes. Slides were developed for 10 minutes with 3,3-diaminobenzidine as substrate, before counterstaining with haematoxylin (Sigma-Aldrich, St Louis, MO, USA). Positive ASRGL1 staining in tumour cells was scored without considering subcellular localisation, as separate analysis of nuclear and cytoplasmic signal is reported to have no additional value. 24 For each woman, a staining index (SI) based on all three cylinders was calculated by multiplying staining intensity (range 0-3) and area of positive stained tumour cells (1 = < 10%, 2 = 10-50%, 3 = > 50%). 18, 26, 32 Cut-off for ASRGL1 staining was based on a previous study, 26 defining high ASRGL1 as SI 2-9 and low ASRGL1 as SI 0-1. Random TMAs (n = 160 women) were evaluated by two independent investigators (TF and ILT) to assure inter-observer agreement, and j-value for ASRGL1 in two groups was 0.90. Staining and scoring of ERa and PR have previously been described. 18 
Statistical analysis
Statistical analyses were performed using the SPSS statistical software (version 24.0; IBM Corp., Armonk, NY, USA). All statistical tests were two-sided, and P-values < 0.05 were considered statistically significant. Categorical variables were evaluated using the Pearson chi-square test, whereas continuous variables were analysed using the Mann-Whitney U-test. The Kaplan-Meier method was used to generate disease-specific survival curves, using time of primary surgery as entry date and date of death due to endometrial carcinoma as end point (disease-specific survival). Survival between groups was compared using the log-rank (Mantel-Cox) test. Cox proportional hazard regression model was used for multivariate survival analyses, and binary logistic regression was used to estimate odds ratio for lymph node metastasis. Data are presented according to the STROBE guidelines. 33 
Core outcome sets
No core outcome sets are currently published for endometrial carcinoma. In this study, we have reported diseasespecific survival as the main outcome parameter as described above.
Results
Low expression of ASRGL1 in curettage is associated with aggressive disease and poor outcome in endometrial carcinoma
Curettage samples from 1144 women were evaluated for ASRGL1 expression by IHC. High ASRGL1 expression (Figure 1A) was observed in 80% (n = 917) of women, while 20% (n = 227) of women expressed low levels of ASRGL1 ( Figure 1B) . A total of 484 of these women had hysterectomy samples with known ASRGL1 status, and similar expression of ASRGL1 in the curettage sample and the corresponding hysterectomy specimen was observed in 85% (n = 413) of women (Table 1) . Low ASRGL1 level was significantly associated with high-risk curettage histology and combined ERa/PR loss (P < 0.001 for both, Table 1 ), which are preoperatively assessed parameters related to aggressive endometrial carcinoma. Low expression of ASRGL1 in curettage also predicted high FIGO stage, high grade and ≥ 50% myometrial infiltration in the corresponding hysterectomy specimen (Table 1) . A significant association between low ASRGL1 in curettage and nonendometrioid histology in primary tumour was found (P < 0.001, Table 1 ), particularly evident in women with clear-cell endometrial carcinomas where 60% of curettage samples demonstrated low ASRGL1 level. Low expression of ASRGL1 was associated with poor disease-specific survival (P < 0.001, Figure 1C) , and ASRGL1 expression also had independent negative prognostic value in Cox survival analysis after adjusting for age, FIGO stage, histological type and grade, with a hazard ratio of 1.63 (95% CI 1.11-2.37, P = 0.012, Table 2 ). Additionally, women with low expression of ASRGL1 had significantly worse 5-year overall survival (0.60 versus 0.83, P < 0.001) and progressionfree survival (0.52 versus 0.79, P < 0.001) compared with women with high ASRGL1 expression.
ASRGL1 expression is significantly associated with tumour volume measured in preoperative MRI
Both preoperative MRI and ASRGL1 data were available for 139 women with endometrial carcinoma treated at Haukeland University Hospital. Of these, women with low ASRGL1 expression had significantly larger tumour volume (mean: 43.8 ml) compared with women with high ASRGL1 expression (mean: 16.5 ml, P = 0.026; see Supplementary material, Table S1 ). Tumours with low expression of ASRGL1 also tended to have reduced blood flow compared with tumours with high expression of ASRGL1 (P = 0.078; see Supplementary material, Table S1 ). No significant associations were found between ASRGL1 expression and apparent diffusion coefficient value or the transfer constant from extravascular extracellular space to blood.
18 F-FDG PET/CT images were available from 89 women. ASRGL1 was not found to be associated with any of the metabolic 18 F-FDG PET/CT parameters (see Supplementary material, Table S1 ).
ASRGL1 predicts poor outcome within the subgroup with low-risk curettage histology
Within the group of women with low-risk curettage histology, 764 (88%) women expressed high levels and 102 (12%) women expressed low levels of ASRGL1. Low expression of ASRGL1 was found to associate with postoperatively assessed clinicopathological parameters related to aggressive disease, including high FIGO stage, nonendometrioid histology and high grade (P < 0.001 in all; see Supplementary material, Table S2 ). Women with low ASRGL1 expression in curettage had significantly reduced disease-specific survival compared with those with high levels of ASRGL1 (P < 0.001; see Supplementary material, Figure S1 ). When adjusting for age and FIGO stage, ASRGL1 expression independently predicted poor survival within the subgroup of women with low-risk curettage histology, with an adjusted hazard ratio of 2.54 (95% CI 1.44-4.47, P = 0.001; see Supplementary material, Table S3 ). Women with low expression of ASRGL1 also had significantly worse 5-year overall survival (0.75 versus 0.87, P = 0.001) and progression-free survival (0.65 versus 0.83, P < 0.001) compared with women with high ASRGL1 expression.
Low ASRGL1 expression in curettage predicts lymph node metastases
Information about nodal status was available for 829 women. The frequency of lymph node metastases was significantly higher in women with low ASRGL1 expression compared with those with high ASRGL1 levels (23% versus 10%, respectively, P < 0.001, Table 1 ). Also within the subgroup with low-risk curettage histology, women with low ASRGL1 expression more often had metastatic lymph nodes compared with women expressing high levels of ASRGL1 (18% versus 8%, respectively, P = 0.003; see Supplementary material, Table S2 ). Both curettage histology and low ASRGL1 level predicted the presence of metastatic nodes in a univariate model (P < 0.001 for both), and ASRGL1 was found to independently predict lymph node metastases when adjusting for curettage histology risk (odds ratio 2.07, 95% CI 1.27-3.38, P = 0.003, Table 3 ).
Discussion
Main findings
We find that 20% of women with endometrial carcinoma have low expression of ASRGL1 in curettage samples. We also find that 85% of women with known ASRGL1 status in postoperative samples have similar ASRGL1 expression in curettage samples and the corresponding hysterectomy specimen. Low expression of ASRGL1 in curettage is significantly associated with features of aggressive endometrial carcinoma and is an independent predictor of poor outcome. Interestingly, ASRGL1 expression also demonstrates independent prognostic value within the subgroup of women with low-risk curettage histology.
When relating ASRGL1 status in curettage to preoperative imaging data, we find that tumour size determined by MRI is significantly larger in tumours with low expression of ASRGL1 compared with tumours with high levels of ASRGL1. However, no metabolic 18 F-FDG PET/CT parameters associate with ASRGL1 expression.
Finally, we find that low expression of ASRGL1 in a curettage specimen is significantly associated with the presence of metastatic lymph nodes in univariate models and independently predicts lymph node metastases when adjusted for curettage histology risk.
Strengths and limitations
A major strength of this study is the large, prospectively collected multicentre patient cohort with extensive clinical information and long follow-up time. Additionally, ASRGL1 expression has been related to parameters that are available to surgeons preoperatively (including routine pathology and imaging data) in order to mimic the clinical setting as closely as possible.
As we are the first to identify low ASRGL1 expression in curettage samples as an independent predictor of lymph node metastases, current findings should be validated in separate patient cohorts with sufficient sample sizes. 34 The optimal staining evaluation and cut-off for ASRGL1 need to be standardised before clinical implementation. However, different methods (the staining index 26 versus percentage of cells with positive staining 24, 25 ) for evaluation of ASGRL1 expression have been published with very similar results, indicating that ASRGL1 might be a robust biomarker.
Interpretation
Correct preoperative risk assessment is crucial when planning surgical procedures in women with endometrial carcinoma. The ability to identify women who will benefit from more extensive surgery, full surgical staging and adjuvant therapy at an early time-point may reduce the number of women experiencing recurrent disease -especially important in the low-risk group. Immunohistochemical markers in curettage samples are suggested to improve preoperative risk stratification, and several candidate prognostic markers such as ERa, PR, L1CAM, p53 and Ki-67 have been studied. 17, 18, [35] [36] [37] [38] Protein expression assessed by IHC staining is found to be relatively similar in curettage samples and corresponding hysterectomy specimens for several markers (concordance rates of 70-100%), suggesting that immunohistochemical evaluation of curettage specimens may aid in the identification of high-risk cases before surgery. 35, 38, 39 Loss of ASRGL1 expression in the hysterectomy specimen is found to independently predict aggressive disease and poor disease-specific survival in women with endometrial carcinoma. 24, 26 Less is known about ASRGL1 expression in preoperative samples, but combined low expression of ASRGL1 and PR was recently reported to predict high FIGO stage (III-IV) among women with endometrioid endometrial carcinoma. 25 This is in agreement with our *Cases with data available for all variables included in the univariate analyses (n = 1078). **Based on hysterectomy specimen. findings where low ASRGL1 levels associate with high FIGO stage, both in the whole patient population and in women with a preoperative low-risk histology.
Advanced imaging modalities such as MRI and 18 F-FDG PET are reported to identify women with endometrial carcinoma with advanced disease and poor outcome before surgery. 12, 13, 40, 41 However, these procedures are costly and not all hospitals use such imaging as part of the preoperative examination. Immunohistochemical biomarkers may be used preoperatively with or without imaging as a supplement to improve information available for clinicians when planning surgery. We find that tumour size determined by MRI is significantly larger in tumours with low expression of ASRGL1 than in tumours with high levels of ASRGL1. This supports that a low ASRGL1 level in curettage is a marker of aggressive disease, as large preoperative tumour size at MRI is reported to predict deep myometrial invasion, the presence of lymph node metastases and poor survival in endometrial carcinoma.
14 Lymph node metastasis is associated with aggressive disease and poor outcome in endometrial carcinoma. Lymphadenectomy is not proven to improve disease-free or overall survival in women with assumed low-stage endometrial carcinoma 42 and is associated with an increased risk of surgical complications and long-term sequelae, including lymphoedema. 43 Selection criteria for lymphadenectomy are not uniformly standardised between countries, and the proportion of women undergoing this procedure varies. 44, 45 Sentinel lymph node mapping is increasingly applied in several institutions and may be a good alternative to full lymphadenectomy in women where assessment of nodal status is required. 46, 47 However, this is an intraoperative procedure and does not eliminate the need for preoperative markers that can identify high-risk patients. Presently, a substantial part of women with endometrial carcinoma with assumed low-risk disease are treated at hospitals that do not have the equipment to perform sentinel lymph node mapping. In such cases, preoperative biomarkers may aid in identifying women who may benefit from increased surgical staging and hence referral to secondary or tertiary centres. Even in highly equipped institutions, preoperative biomarkers may be used to select which women should undergo sentinel lymph node mapping. By not performing this procedure on all women, but rather only the ones with high risk of lymph node metastases, both operation time and costs could potentially be reduced. Especially, women with high risk of comorbidities/increased complication rates (such as high age and obese women) may benefit from avoiding extended surgery due to lymph node assessment.
We find that low expression of ASRGL1 in the curettage specimen is significantly associated with metastatic lymph nodes in univariate models and that low ASRGL1 expression independently predicts lymph node metastases when adjusted for curettage histology risk. This suggests ASRGL1 as a promising biomarker that could potentially improve the currently performed preoperative risk stratification. These findings must be validated in independent studies, and prospective trials should be conducted to assess the performance of ASRGL1 in a clinical setting.
L-Asparaginase has been the cornerstone of treatments for acute lymphoblastic leukaemia and non-Hodgkin's lymphoma for many years, and is suggested to have therapeutic potential in other malignancies including pancreatic and ovarian cancers. [48] [49] [50] [51] As ASRGL1 is demonstrated to have L-asparaginase activity in vitro, it is tempting to speculate if treatment with L-asparaginases could have therapeutic effects in women with ASRGL1 loss. Altogether, ASRGL1 is a biomarker that may potentially be important in several stages of endometrial carcinoma treatment, both preoperatively (to identify women who should undergo more radical surgical staging), postoperatively (to identify women that should receive adjuvant treatment) and (if proven to be effective) in predicting which women may respond to L-asparaginase therapy.
Conclusion
Low ASRGL1 expression in curettage predicts lymph node metastases and has independent prognostic value both in the whole patient population and within the subgroup of low-risk patients. ASRGL1 status may add valuable prognostic information to the existing preoperative risk stratification system in endometrial carcinoma.
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